MX2023012541A - Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan. - Google Patents
Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan.Info
- Publication number
- MX2023012541A MX2023012541A MX2023012541A MX2023012541A MX2023012541A MX 2023012541 A MX2023012541 A MX 2023012541A MX 2023012541 A MX2023012541 A MX 2023012541A MX 2023012541 A MX2023012541 A MX 2023012541A MX 2023012541 A MX2023012541 A MX 2023012541A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- pharmaceutically acceptable
- acceptable salt
- inhibitory activity
- activity against
- Prior art date
Links
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 title abstract 6
- 108091000114 ceramide glucosyltransferase Proteins 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 abstract 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 208000015872 Gaucher disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000022292 Tay-Sachs disease Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona un nuevo compuesto que tiene una actividad inhibidora contra la glucosilceramida sintasa (GCS), es decir, compuestos que tienen un grupo funcional de 2,3-dihidro-1H-indeno, 1,2,3,4-tetrahidronaftaleno o cromano, o una sal farmacéuticamente aceptable de este, un proceso para la preparación de este, una composición farmacéutica que lo comprende y un uso del mismo. El compuesto o la sal farmacéuticamente aceptable del mismo tiene una actividad inhibidora contra la glucosilceramida sintasa (GCS), y exhibe los efectos de aliviar los síntomas en el sistema nervioso central, así como en el sistema nervioso periférico, a través de una excelente permeabilidad de la barrera hematoencefálica. Por lo tanto, el compuesto o la sal farmacéuticamente aceptable de este puede aplicarse de forma útil para prevenir o tratar diversas enfermedades asociadas a la GCS, como la enfermedad de Gaucher, la enfermedad de Fabry, la enfermedad de Tay-Sachs, la enfermedad de Parkinson, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210060942 | 2021-05-11 | ||
| PCT/KR2022/006613 WO2022240116A1 (en) | 2021-05-11 | 2022-05-10 | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012541A true MX2023012541A (es) | 2023-11-03 |
Family
ID=84029335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012541A MX2023012541A (es) | 2021-05-11 | 2022-05-10 | Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262819A1 (es) |
| EP (1) | EP4308561A1 (es) |
| JP (1) | JP2024518301A (es) |
| KR (1) | KR20220153511A (es) |
| CN (1) | CN117222645A (es) |
| AU (1) | AU2022272851A1 (es) |
| BR (1) | BR112023022015A2 (es) |
| CA (1) | CA3216293A1 (es) |
| IL (1) | IL306116A (es) |
| MX (1) | MX2023012541A (es) |
| WO (1) | WO2022240116A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| ES2774293T3 (es) * | 2011-03-18 | 2020-07-20 | Genzyme Corp | Inhibidores de la glucosilceramida sintasa |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| US20170121385A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| KR20210059633A (ko) * | 2019-11-15 | 2021-05-25 | 주식회사유한양행 | 신규의 1,2,3,4-테트라하이드로나프탈렌 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
-
2022
- 2022-05-10 US US18/559,466 patent/US20240262819A1/en active Pending
- 2022-05-10 EP EP22807764.0A patent/EP4308561A1/en active Pending
- 2022-05-10 KR KR1020220057000A patent/KR20220153511A/ko unknown
- 2022-05-10 CN CN202280029853.0A patent/CN117222645A/zh active Pending
- 2022-05-10 CA CA3216293A patent/CA3216293A1/en active Pending
- 2022-05-10 IL IL306116A patent/IL306116A/en unknown
- 2022-05-10 BR BR112023022015A patent/BR112023022015A2/pt unknown
- 2022-05-10 AU AU2022272851A patent/AU2022272851A1/en active Pending
- 2022-05-10 MX MX2023012541A patent/MX2023012541A/es unknown
- 2022-05-10 JP JP2023564546A patent/JP2024518301A/ja active Pending
- 2022-05-10 WO PCT/KR2022/006613 patent/WO2022240116A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024518301A (ja) | 2024-05-01 |
| EP4308561A1 (en) | 2024-01-24 |
| BR112023022015A2 (pt) | 2023-12-26 |
| KR20220153511A (ko) | 2022-11-18 |
| IL306116A (en) | 2023-11-01 |
| US20240262819A1 (en) | 2024-08-08 |
| WO2022240116A1 (en) | 2022-11-17 |
| CN117222645A (zh) | 2023-12-12 |
| AU2022272851A1 (en) | 2023-10-05 |
| CA3216293A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005679A (es) | Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. | |
| Lee et al. | Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens | |
| J Geldenhuys et al. | Rationally designed multi-targeted agents against neurodegenerative diseases | |
| MX2010002115A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2008011611A3 (en) | Compounds and compositions as itpkb inhibitors | |
| MY148982A (en) | Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals | |
| BRPI0518898A2 (pt) | composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto | |
| MX2009004908A (es) | Compuestos quimicos. | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| CA3070206A1 (en) | Compounds affecting pigment production and use thereof for treatment of bacterial diseases | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| PH12014502802A1 (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| MX2010010877A (es) | Compuestos y composiciones como inhibidores de itpkb. | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| BR0315346A (pt) | Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a | |
| MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
| MX2021012487A (es) | Compuestos derivados de pirazolopirazina, composicion farmaceutica y uso de la misma. | |
| MX2023012541A (es) | Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan. | |
| MX2023011297A (es) | Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6). | |
| CR20220554A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas | |
| MX2023000437A (es) | Derivado de bencisoxazol. | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto |